JP6599773B2 - 抗体を精製するための方法 - Google Patents

抗体を精製するための方法 Download PDF

Info

Publication number
JP6599773B2
JP6599773B2 JP2015562513A JP2015562513A JP6599773B2 JP 6599773 B2 JP6599773 B2 JP 6599773B2 JP 2015562513 A JP2015562513 A JP 2015562513A JP 2015562513 A JP2015562513 A JP 2015562513A JP 6599773 B2 JP6599773 B2 JP 6599773B2
Authority
JP
Japan
Prior art keywords
protein
acid
sodium
wash buffer
tris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015562513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519052A5 (enExample
JP2016519052A (ja
Inventor
イー. ゴクレン,ケント
ジェイ. スダ,エリック
ラウル ウビエラ,アントニオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6599773(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2016519052A publication Critical patent/JP2016519052A/ja
Publication of JP2016519052A5 publication Critical patent/JP2016519052A5/ja
Application granted granted Critical
Publication of JP6599773B2 publication Critical patent/JP6599773B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015562513A 2013-03-15 2014-03-13 抗体を精製するための方法 Active JP6599773B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787309P 2013-03-15 2013-03-15
US61/787,309 2013-03-15
PCT/IB2014/059755 WO2014141150A1 (en) 2013-03-15 2014-03-13 Methods for purifying antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019182562A Division JP7002511B2 (ja) 2013-03-15 2019-10-03 抗体を精製するための方法

Publications (3)

Publication Number Publication Date
JP2016519052A JP2016519052A (ja) 2016-06-30
JP2016519052A5 JP2016519052A5 (enExample) 2017-03-30
JP6599773B2 true JP6599773B2 (ja) 2019-10-30

Family

ID=50391244

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015562513A Active JP6599773B2 (ja) 2013-03-15 2014-03-13 抗体を精製するための方法
JP2019182562A Active JP7002511B2 (ja) 2013-03-15 2019-10-03 抗体を精製するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019182562A Active JP7002511B2 (ja) 2013-03-15 2019-10-03 抗体を精製するための方法

Country Status (15)

Country Link
US (3) US10676503B2 (enExample)
EP (3) EP4371996A3 (enExample)
JP (2) JP6599773B2 (enExample)
KR (1) KR102114021B1 (enExample)
CN (1) CN105188872B (enExample)
AU (1) AU2014229280B2 (enExample)
BR (1) BR112015022321A2 (enExample)
CA (1) CA2902287A1 (enExample)
DK (2) DK3680000T3 (enExample)
ES (2) ES2765206T3 (enExample)
IL (1) IL240753B (enExample)
RU (1) RU2651483C2 (enExample)
SG (1) SG11201506494XA (enExample)
TW (1) TWI625335B (enExample)
WO (1) WO2014141150A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4371996A3 (en) 2013-03-15 2024-08-14 GlaxoSmithKline Intellectual Property Development Limited Methods for purifying antibodies
US10259842B2 (en) 2013-05-15 2019-04-16 Medimmune, Llc Purification of recombinantly produced polypeptides
ES2975172T1 (es) 2014-04-30 2024-07-03 Novo Nordisk As Métodos para la purificación de proteínas usando ácido caprílico
JP6663360B2 (ja) 2015-01-26 2020-03-11 株式会社カネカ 変異型免疫グロブリンκ鎖可変領域結合性ペプチド
JPWO2016121701A1 (ja) 2015-01-26 2017-11-09 株式会社カネカ 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス
WO2017195638A1 (ja) * 2016-05-09 2017-11-16 株式会社カネカ 抗体またはκ鎖可変領域含有抗体断片の精製方法
RU2759909C2 (ru) * 2016-09-07 2021-11-18 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы очистки антител
CN106939045B (zh) * 2017-05-01 2020-03-31 深圳市国创纳米抗体技术有限公司 一种单克隆抗体细胞培养液澄清的方法
CN108085358A (zh) * 2018-02-08 2018-05-29 保定冀中药业有限公司 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法
TW202000891A (zh) 2018-03-07 2020-01-01 英商葛蘭素史克智慧財產發展有限公司 純化抗體之方法
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
CN116234619B (zh) * 2020-08-18 2026-07-21 赛多利斯比亚分离有限责任公司 宿主细胞dna的金属亲和提取
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法
CN116179582A (zh) * 2022-09-27 2023-05-30 南京医事达生物科技有限公司 一种通用型基因重组蛋白质a亲和纯化填料制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6955917B2 (en) 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
ATE515950T1 (de) * 2001-06-01 2011-07-15 Upfront Chromatography As Fraktionierung von proteinhaltigen mischungen
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
WO2003102208A2 (en) 2002-05-31 2003-12-11 Indian Council Of Agricultural Research Rapid detection of bt-cry toxins
CA2557229C (en) * 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
US20050272917A1 (en) * 2004-05-14 2005-12-08 Hematech, Llc Methods for immunoglobulin purification
US8263750B2 (en) * 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
TW200821026A (en) 2006-09-08 2008-05-16 Wyeth Corp Arginine wash in protein purification using affinity chromatography
WO2008085988A1 (en) * 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
EP2691411B1 (en) 2011-03-29 2020-02-26 GlaxoSmithKline LLC Buffer system for protein purification
EP4371996A3 (en) 2013-03-15 2024-08-14 GlaxoSmithKline Intellectual Property Development Limited Methods for purifying antibodies
US10259842B2 (en) * 2013-05-15 2019-04-16 Medimmune, Llc Purification of recombinantly produced polypeptides
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides

Also Published As

Publication number Publication date
EP3680000A1 (en) 2020-07-15
ES2765206T3 (es) 2020-06-08
DK2969098T3 (da) 2020-01-27
EP2969098B1 (en) 2019-10-30
AU2014229280A1 (en) 2015-10-01
TW201522365A (zh) 2015-06-16
AU2014229280B2 (en) 2017-01-05
US20250353878A1 (en) 2025-11-20
IL240753B (en) 2021-01-31
JP2016519052A (ja) 2016-06-30
EP4371996A3 (en) 2024-08-14
JP2020019795A (ja) 2020-02-06
BR112015022321A2 (pt) 2017-07-18
WO2014141150A1 (en) 2014-09-18
US10676503B2 (en) 2020-06-09
KR20150131235A (ko) 2015-11-24
US12358945B2 (en) 2025-07-15
ES2978309T3 (es) 2024-09-10
US20160024146A1 (en) 2016-01-28
RU2015136860A (ru) 2017-04-28
KR102114021B1 (ko) 2020-05-22
CN105188872A (zh) 2015-12-23
TWI625335B (zh) 2018-06-01
CN105188872B (zh) 2019-01-15
JP7002511B2 (ja) 2022-02-21
EP3680000B1 (en) 2024-03-13
CA2902287A1 (en) 2014-09-18
EP4371996A2 (en) 2024-05-22
DK3680000T3 (da) 2024-04-02
SG11201506494XA (en) 2015-09-29
RU2651483C2 (ru) 2018-04-19
EP2969098A1 (en) 2016-01-20
IL240753A0 (en) 2015-10-29
US20200277330A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
JP7002511B2 (ja) 抗体を精製するための方法
JP6147726B2 (ja) タンパク質精製のためのバッファー系
JP7058272B2 (ja) 抗体を精製するための方法
EP3762411A1 (en) Methods for purifying recombinant polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151117

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191003

R150 Certificate of patent or registration of utility model

Ref document number: 6599773

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250